Blue Jet Healthcare shares rallied more than 15% over the last two trading sessions despite the company reporting weak Q4 FY26 earnings, as investors focused on sequential profit recovery, the proposed Rs 1,000 crore fundraising plan, and future growth expectations.
The stock had surged nearly 10% on Monday and gained another over 5% on Tuesday, with shares trading around Rs 512 levels after settling at Rs 483.90 on the NSE in the previous session.
The company reported Q4 FY26 net profit of Rs 64.34 crore, which was sharply lower on a year-on-year basis compared to Rs 110 crore in the corresponding quarter last year. Revenue from operations also declined 31.1% YoY to Rs 234.67 crore.
However, market participants appeared to focus more on the sequential recovery in earnings. Net profit rose around 60% quarter-on-quarter from Rs 40.16 crore reported in the December quarter, indicating improvement in operational momentum compared to the previous quarter.
Another major trigger for the rally was the company’s announcement to raise up to Rs 1,000 crore through equity shares or other eligible instruments. Investors are likely interpreting the proposed fundraising as a sign of expansion ambitions and long-term growth planning by the specialty pharmaceutical company.
Blue Jet Healthcare also announced that it will hold an extraordinary general meeting on June 17, 2026, to seek shareholder approval for the proposed capital raise.
Additionally, the board recommended a final dividend of Rs 1.2 per equity share of face value Rs 2 each for FY26, subject to shareholder approval.
Blue Jet Healthcare operates in the specialty pharmaceutical segment with focus on contrast media intermediates and high-value active pharmaceutical ingredients (APIs), areas that continue to attract investor interest due to their export potential and niche positioning.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.